VolitionRx Q2 2024 Earnings Report $0.63 -0.01 (-2.17%) As of 01/17/2025 03:59 PM Eastern Earnings HistoryForecast VolitionRx EPS ResultsActual EPS-$0.08Consensus EPS -$0.09Beat/MissBeat by +$0.01One Year Ago EPSN/AVolitionRx Revenue ResultsActual Revenue$0.40 millionExpected Revenue$0.34 millionBeat/MissBeat by +$60.00 thousandYoY Revenue GrowthN/AVolitionRx Announcement DetailsQuarterQ2 2024Date8/14/2024TimeN/AConference Call ResourcesVNRX Earnings History VolitionRx Earnings HeadlinesVolitionRx's (VNRX) Buy Rating Reiterated at D. Boral CapitalJanuary 11, 2025 | americanbankingnews.comVolition Issues Business Review 2024January 8, 2025 | prnewswire.comDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.January 19, 2025 | Brownstone Research (Ad)VolitionRx Appoints LifeSci Advisors as Investor Relations ConsultantsDecember 12, 2024 | prnewswire.comStudy shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screeningDecember 10, 2024 | prnewswire.comVolitionRx Announces Pricing of up to $1.9 Million Registered Direct OfferingDecember 6, 2024 | prnewswire.comSee More VolitionRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like VolitionRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VolitionRx and other key companies, straight to your email. Email Address About VolitionRxVolitionRx (NYSE:VNRX), a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.View VolitionRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)HDFC Bank (1/21/2025)Charles Schwab (1/21/2025)Prologis (1/21/2025)3M (1/21/2025)Capital One Financial (1/21/2025)ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
